Acacia Pharma (EU: ACPH)

Last close As at 04/02/2025

1.28

0.04 (3.23%)

Market capitalisation

129m

Edison Investment Research is terminating coverage on Acacia Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

Acacia Pharma — Progressing on all-important formulary wins

Healthcare | Update

Acacia Pharma — BARHEMSYS and BYFAVO launched in the US

Healthcare | Update

Acacia Pharma — Two US drug launches in 2020

Healthcare | Update

Acacia Pharma — BYFAVO receives FDA approval

Flash note

Healthcare

Acacia Pharma — Michael Bolinder to become CEO

Update

Healthcare

Acacia Pharma — Ready for BARHEMSYS launch in H119

Flash note

Healthcare

Acacia Pharma — H119 launch remains on track for BARHEMSYS

Update

Healthcare

Acacia Pharma — BARHEMSYS NDA resubmitted to FDA

Update

Healthcare

Acacia Pharma — FDA issues CRL for BARHEMSYS

Initiation

Healthcare

Acacia Pharma — Raising the BAR in PONV